Patents by Inventor Katalin Kariko

Katalin Kariko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11060107
    Abstract: This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 13, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Drew Weissman, Katalin Kariko
  • Patent number: 11028370
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 8, 2021
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Publication number: 20210024895
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Application
    Filed: March 23, 2020
    Publication date: January 28, 2021
    Applicants: The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Publication number: 20200399629
    Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Applicant: BioNTech RNA Pharmaceuticals GmbH
    Inventors: Katalin Kariko, Ugur Sahin
  • Patent number: 10808242
    Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 20, 2020
    Assignee: BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Katalin Kariko, Ugur Sahin
  • Publication number: 20200030460
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 30, 2020
    Inventors: Katalin Kariko, Drew Weissman
  • Publication number: 20190153428
    Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.
    Type: Application
    Filed: August 24, 2016
    Publication date: May 23, 2019
    Inventors: Katalin KARIKO, Ugur SAHIN
  • Publication number: 20190153425
    Abstract: The present invention relates to methods for providing single-stranded RNA (ssRNA). Furthermore, the present invention relates to the ssRNA which is obtainable by the methods of the invention and the use of such ssRNA in therapy.
    Type: Application
    Filed: April 19, 2017
    Publication date: May 23, 2019
    Inventors: Markus Baiersdorfer, Katalin Kariko
  • Patent number: 10232055
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 19, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman
  • Publication number: 20180265848
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 20, 2018
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Patent number: 10006007
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 26, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Publication number: 20170327842
    Abstract: This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 16, 2017
    Inventors: Drew Weissman, Katalin Kariko
  • Patent number: 9750824
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: September 5, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman
  • Publication number: 20170043037
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Inventors: Katalin Kariko, Drew Weissman
  • Publication number: 20160369243
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Application
    Filed: May 20, 2016
    Publication date: December 22, 2016
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Patent number: 9371511
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 21, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Publication number: 20160032316
    Abstract: This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Drew Weissman, Katalin Kariko
  • Publication number: 20160030527
    Abstract: The present invention provides compositions and methods for treating stroke. The invention relates to inhibiting the level and/or activity of cell debris after the onset of stroke. In certain embodiments, the invention provides for the catabolism or inhibition of at least one of extracellular RNA, extracellular DNA, and extracellular ATP.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman
  • Publication number: 20150315572
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 5, 2015
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Patent number: 9163213
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: October 20, 2015
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak